NICE Rejection Of Celgene's Otezla Finalized; Four JIA Drugs Reviewed
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has issued final guidance not recommending Celgene's psoriatic arthritis drug Otezla (apremilast) for use on the National Health Service; but the committee has given the nod to four products for the treatment of juvenile idiopathic arthritis.